c 12241 (PromoCell)
Structured Review
C 12241, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 93 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c+12241/Human+Pulmonary+Artery+Endothelial+Cells/pm41227316-64-5-4
Average 95 stars, based on 93 article reviews
Images
Related Articles
Isolation:Article Title: Transmembrane Protein 100 Expression on Endothelial Cells Vascularizing Thrombi in Chronic Thromboembolic Pulmonary Hypertension Modulates TGFβ1−ALK1 Signaling During Angiogenesis Article Snippet: .. CTEPH‐ECs (Passage 1; Ethics Approval AZ 199/15) were isolated from CTEPH PEA specimens, as described in Bochenek et al. [ ], and compared to human Cell Culture:Article Title: Endothelial cell responses in sepsis are attenuated by targeting truncated procalcitonin Article Snippet: .. Article Title: Caspase-6 Is a Non-Apoptotic Effector of Shear-Induced Morphological Adaptation in Pulmonary Artery Endothelial Cells In Vitro. Article Snippet: .. Cells were obtained from PromoCell (# Article Title: Activin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH Article Snippet: .. Article Title: Activin A–Endothelin-1 Axis Governs Pulmonary Vascular Remodeling: Mechanistic Basis for Emerging Therapies in PAH Article Snippet: Arterioscler Thromb Vasc Biol.. 2026;46:e323681.. DOI: 10.1161/ATVBAHA.125.323681 May 2026 1 Arterioscler Thromb Vasc Biol is available at www.ahajournals.org/journal/atvb Correspondence to: Gusty Rizky Teguh Ryanto, MD, PhD, Laboratory of Clinical Pharmaceutical Science, 658-8558, 4-19-1 Motoyama Kitamachi, Higashinada, Kobe, Hyogo, Japan, Email gryanto@kobepharma-u.ac.jp; or Noriaki Emoto, MD, PhD, Laboratory of Clinical Pharmaceutical Science, 658-8558, 4-19-1 Motoyama Kitamachi, Higashinada, Kobe, Hyogo, Japan, Email emoto@kobepharma-u.ac.jp Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/ATVBAHA.125.323681. |
![In vivo activin A inhibition improves <t>pulmonary</t> hypertension (PH) phenotype comparably or more than ET-1 (endothelin-1) blockade. A , Experimental design: wild-type (WT) and VE-cadherin (vascular endothelial cadherin)–INHBA (inhibin β-A)-Tg (TG/transgenic) mice were exposed to hypoxia (10% O 2 ) for 3 weeks, with vehicle (VEH), FST (follistatin; 8.5 μg/kg), bosentan (BOS; 30 mg/kg), or FST+BOS administered during the final 2 weeks. B , Right ventricular systolic pressure (RVSP; n=4–9). C , Fulton index (RV/[LV+S] [right ventricle to left ventricle plus septum] ratio; n=4–8). D , Representative hematoxylin and eosin–stained lung sections. Blue arrows indicate vessels. E , Representative immunofluorescent staining of α-SMA (α-smooth muscle actin protein; green, SMC [smooth muscle cell] marker), vWF (von Willebrand Factor; red, endothelial cell [EC] marker), and DAPI (4′,6-diamidino-2-phenylindole; blue, nuclei). White arrows indicate vessels. F , Quantification of pulmonary <t>artery</t> muscularization (non-, partial-, full; n=12–15 fields from 3–4 mice). PA indicates pulmonary artery. G , Lung ET-1 mRNA expression (n=3–4). H , mRNA expression of INHBA, ET-1, eNOS (endothelial NO synthase), SOD2 (superoxide dismutase 2), fibronectin, SLUG (snail family transcriptional repressor 2), CD31 (cluster of differentiation 31), and BMP4 (bone morphogenetic protein 4) in lung <t>ECs</t> isolated from WT and TG mice (n=3–4). Data are mean±SEM. P <0.05 is deemed statistically significant. Tests: 1-way ANOVA with Tukey post hoc test for B , C , and G ; 2-way ANOVA with Tukey post hoc test for F ; 2-sided Student t test for H .](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_8652/pmc13098652/pmc13098652__atv-46-e323681-g006.jpg)
